Last update 08 May 2025

CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)

Overview

Basic Info

Drug Type
Universal CAR-T
Synonyms-
Target
CD38
Action
modulators
Mechanism
CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Plasma Cell LeukemiaRefractory acute myeloid leukemiaAcute Lymphoblastic Leukemia+ [2]
Inactive Indication-
Originator Organization
Shenzhen Geno-Immune Medical Institute
Active Organization
Shenzhen Geno-Immune Medical Institute
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)
NCT06006741
/ RecruitingPhase 1IIT
Universal CAR-T Cells for the Treatment of Multiple Myeloma
NCT05995041
/ RecruitingPhase 1IIT
Universal CAR T Cells for the Treatment of Acute Myeloid Leukemia
100 Clinical Results associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Translational Medicine associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Patents (Medical) associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Deals associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plasma Cell LeukemiaPhase 1
China
Shenzhen Geno-Immune Medical Institute
31 Oct 2023
Refractory acute myeloid leukemiaPhase 1
China
Shenzhen Geno-Immune Medical Institute
31 Oct 2023
Acute Lymphoblastic LeukemiaPhase 1
China
Shenzhen Geno-Immune Medical Institute
05 May 2018
Myelodysplastic SyndromesPhase 1
China
Shenzhen Geno-Immune Medical Institute
05 May 2018
Refractory LeukemiaPhase 1
China
Shenzhen Geno-Immune Medical Institute
05 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free